Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The current standard treatment of resectable esophageal cancer consists of neoadjuvant chemoradiation followed by resection. However, some patients develop recurrent disease despite chemoradiation and additional (systemic) treatment might have been indicated. Other patients show a (nearly) complete response after chemoradiation and could possibly have been treated with a less extensive treatment regimen. In patients without a threatened circumferential resection margin (CRM) and lymph node metastases chemoradiotherapy could possibly be omitted.

Better stratification of patients with esophageal cancer is therefore urgently needed. Functional magnetic resonance imaging techniques (MRI) can provide in vivo, quantitative information on tumor biology and may prove to be a useful non-invasive tool for this purpose. In this project, ultra-small superparamagnetic particles of iron oxide (USPIO) enhanced MRI using ferumoxytol (Rienso®), diffusion weighted MRI (DWI) and T2* MRI will be developed, both in terms of improvement of acquisition and data processing techniques.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Treatments: Ferrosoferric Oxide

Criteria

Inclusion Criteria:

• Patients with biopsy proven esophageal cancer (squamous cell carcinoma or adenocarcinoma)

• Suspected nodal involvement on EUS or CT at diagnosis.

• WHO-performance score 0-2

• Scheduled for surgery

• Written informed consent

Exclusion Criteria:

• Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol

• Contra-indications for MR scanning, including patients with a pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; or a non-MR compatible aneurysm clip in their brain; patients with severe claustrophobia

• Active inflammatory diseases

• History of anaphylaxis or other hypersensitivity reactions

• History of iron overload

• History of abnormal liver function, or elevated liver enzymes (ALAT, ASAT > 3 times upper limit of normal)

• Elevated Serum Transferrin Saturation (TSAT) (>50%) or hemoglobin (>10.5mmol/L)